We hypothesized that the selection of a donor cohort with a shared underlying pathology would enable us to determine the temporal changes of biomarkers of brain injury (neuron-specific enolase [NSE], glial fibrillary acidic protein [GFAP]—to reflect neuronal and glial injury, respectively) and proinflammatory mediators (TNF-α, interleukin-6 [IL-6], and complement), from confirmation of BD through to organ recovery. The gene discussed is ENO2; the disease is Behcet disease.